Who are TAP-144-SR(3M)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Half-Dose Depot Triptorelin, Degarelix (LHRH antagonist), GnRH agonist trigger, cetrorelix (cetrotide).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tap-144-sr-3m.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TAP-144-SR(3M) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAP-144-SR(3M) (TAP-144-SR(3M)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology.

phase 3 GnRH agonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAP-144-SR(3M) (TAP-144-SR(3M)) — Takeda. TAP-144-SR is a sustained-release formulation of leuprolide, a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce sex hormone production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAP-144-SR(3M) TARGET	TAP-144-SR(3M)	Takeda	phase 3	GnRH agonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor
Degarelix (LHRH antagonist)	Degarelix (LHRH antagonist)	Rabin Medical Center	marketed	GnRH antagonist	GnRH receptor
GnRH agonist trigger	GnRH agonist trigger	Rambam Health Care Campus	marketed	GnRH agonist	GnRH receptor
cetrorelix (cetrotide)	cetrorelix (cetrotide)	Eugonia	marketed	GnRH antagonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist class)

Takeda · 4 drugs in this class
Abbott · 3 drugs in this class
Ipsen · 3 drugs in this class
Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
University of Pisa · 2 drugs in this class
Chong Qing Reproducive and Genetic Institute · 1 drug in this class
Chesapeake Urology Research Associates · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Enteris BioPharma Inc. · 1 drug in this class
Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAP-144-SR(3M) — Competitive Intelligence Brief. https://druglandscape.com/ci/tap-144-sr-3m. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing